C07D 491/107
With only one oxygen atom as ring hetero atom in the oxygen-containing
Official title: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
C07D491/107 (With only one oxygen atom as ring hetero atom in the oxygen-containing) appears on 1,254 US grants and 2,035 published applications in this corpus.
Search patents in C07D- Granted patents
- 1,254
- Published applications
- 2,035
- Assignees
- 727
- Inventors
- 6,548
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 2 |
| 2006 | 1 | 4 |
| 2007 | 1 | 8 |
| 2008 | 2 | 13 |
| 2009 | 8 | 30 |
| 2010 | 9 | 34 |
| 2011 | 13 | 48 |
| 2012 | 17 | 52 |
| 2013 | 57 | 91 |
| 2014 | 66 | 97 |
| 2015 | 87 | 119 |
| 2016 | 93 | 127 |
| 2017 | 94 | 104 |
| 2018 | 88 | 97 |
| 2019 | 116 | 125 |
| 2020 | 73 | 135 |
| 2021 | 94 | 138 |
| 2022 | 102 | 146 |
| 2023 | 80 | 179 |
| 2024 | 86 | 182 |
| 2025 | 104 | 170 |
| 2026 | 63 | 133 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- P38alpha mitogen-activated protein kinase inhibitors6 Oct 2026US 12,753,184 B2Gen1E Lifesciences Inc.
- Pharmaceutical compounds and methods of making and using the same29 Sep 2026US 12,747,208 B2Athos Therapeutics, Inc.
- Triazolyl derivatives as GABAA α5 PAM29 Sep 2026US 12,747,235 B2Hoffmann-La Roche Inc.
- Inhibitors and uses thereof22 Sep 2026US 12,740,991 B2Vividion Therapeutics, Inc.
- BRM/BRG1 inhibitors and uses thereof22 Sep 2026US 12,741,966 B2Foghorn Therapeutics Inc.
- 1,3,4-thiadiazol-2-yl carboxamide and 1,3-thiazol-2-yl carboxamide compounds and uses thereof as inhibitors of human polymerase theta1 Oct 2026US 2026/0294921 A1Gilead Sciences, Inc.
- Compounds for the degradation of mutant braf1 Oct 2026US 2026/0297060 A1C4 Therapeutics, Inc.
- Compounds and methods of treating cancers1 Oct 2026US 2026/0297081 A1Cullgen Inc.
- Oxazole trpml1 agonists and uses thereof1 Oct 2026US 2026/0297104 A1Libra Therapeutics, Inc.
- Raf-mek protein complex modulators and methods of use thereof1 Oct 2026US 2026/0297105 A1Gandeeva Therapeutics, Inc.
Most cited
By later US patents
- 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors109US 8,309,718 B2Incyte Corporation · 2012
- Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors99US 8,933,085 B2Incyte Corporation · 2015
- Aryl- or heteroaryl-substituted benzene compounds82US 8,410,088 B2Eisai R&D Management Co., Ltd. · 2013
- Methods of use of cyclopamine analogs72US 8,227,509 B2Infinity Pharmaceuticals, Inc. · 2012
- Aryl- or heteroaryl-substituted benzene compounds59US 8,765,732 B2Epizyme, Inc. · 2014